Drugs / Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07543172 | Sep 2026 → Jun 2029 expected | non-small cell lung carcinoma | Roswell Park Cancer Institute | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07543172 ↗ |
| Modality | Vaccine | “Vaccines, such as CIMAvax-EGF, made from specific peptides or antigens may help the body build an effective immune response to kill tumor cells.” NCT07543172 ↗ |
| Route | Intramuscular | “CIMAvax-EGF intramuscularly” NCT07543172 ↗ |